Diclofenac

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Wobenzym

Conditions

Wobenzym, Osteoarthritis

Trial Timeline

Nov 1, 2000 → Nov 1, 2001

NCT ID

NCT02088411

About Diclofenac

Diclofenac is a phase 2 stage product being developed by Atrium Therapeutics for Wobenzym. The current trial status is completed. This product is registered under clinical trial identifier NCT02088411. Target conditions include Wobenzym, Osteoarthritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02088411	Phase 2	Completed	Nov 1, 2000	Nov 1, 2001	Wobenzym

Other Products from Atrium Therapeutics

Rivastigmine + Placebo (for rivastigmine)Approved

Phenoxybenzamine + DoxazosinApproved

Ropivacaine HCL + Exparel + Epinephrine + Clonidine HCL + KetorolacPhase 3

Metformin Hydrochloride ERPhase 2

VaccinePhase 2